Immnuocellular, IMUC, Profile, Summary
Immnuocellular Therapeutics | IMUC | Profile | Summary
ImmunoCellular Therapeutics is developing immune-based therapies for the treatment of brain cancer and other tumors. Our lead product candidate, ICT-107, is a dendritic cell-based vaccine targeting multiple tumor-associated antigens for glioblastoma multiforme (GBM), the most common and lethal type of brain cancer. Our pipeline also includes ICT-121, a dendritic cell (DC) vaccine targeting CD133, and ICT-140, a dendritic cell vaccine targeting ovarian cancer antigens and cancer stem cells.
ImmunoCellular Therapeutics aims to become an industry-leading, independent, commercial-stage cancer immunotherapy company serving patients in major markets.
ImmunoCellular Cancer Vaccine Manufacturing Process
Each of ImmunoCellular’s dendritic cell (DC) vaccines is prepared from blood collected from each patient. The process, which takes only a few days to complete, is designed to generate sufficient cryopreserved (frozen) cells for dosing through the induction and maintenance phases of immunotherapy. Our GMP manufacturing process adheres strictly to standard operating procedures to ensure consistency, quality and sterility.
The process begins with an apheresis (also referred to as leukapheresis), a common procedure in which the patient’s blood is circulated through a machine to collect the white blood cells.
ImmunoCellular Therapeutics’ proprietary cancer vaccine immunotherapy technology has the potential to transform the treatment of cancer by improving survival and offering safer and more effective treatments than conventional cancer therapies. Our dendritic cell (DC)-based immunotherapies are designed to target both tumor cells as well as cancer stem cells by utilizing multiple tumor-specific antigens to trigger a powerful antitumor immune system response. Utilizing an advanced manufacturing process, we can produce multiple doses from a single apheresis, and offer the advantages of potency, versatility, efficiency, cost-effectiveness and convenience compared to earlier generation cancer vaccines.
Our dendritic cell (DC) vaccine technology and advanced manufacturing offer several advantages over earlier-generation cellular immunotherapies:
-
Potency
-
Matured DCs secrete IL12, which is critical for stimulating T cell killing of cancer cells.
-
More than 80% of the final manufactured product consists of matured DCs.
-
-
Versatility
-
Unlike other cell-based vaccines, our DCs target multiple antigens, thus increasing the likelihood of effective treatment.
-
-
Efficiency
-
Advanced manufacturing enables production of at least 20 doses of vaccine from a single apheresis (blood collection); thus patients do not need to undergo additional apheresis procedures.
-
-
Cost-effectiveness
-
Compared to the only approved cell-based immunotherapy, our DC vaccines can be manufactured at a significantly reduced cost.
-
-
Convenience
-
Ability to freeze and store vaccine for months or years eliminates the need to administer to the patient shortly after manufacture.
-
Intradermal administration route reduces the time and inconvenience of intravenous infusion for both patient and physician.
-
Source: IMUC, OxBridge Research, Daily Stock Deal, OTCking
Don't miss the NEXT premium Alert! Sign-up, Get Alerts, MakeMoney!®
Disclaimer/Disclosure: we receive compensation from companies we feature on our websites/blogs/emails/newsletters or comment on social media/FB/TWTR etc. Our firm, principals and staff may own/buy/sell/trade stock/securities of this company. Always Read the full Disclosure/Disclaimer. Thanks.
Petro River Oil, PTRC, Profile, Summary
Petro River Oil | PTRC | Profile | Summary
Petro is an emerging oil and gas producer focusing on assets in the Southeast Kansas region of the Mississippi Lime. Petro owns approximately 115,000 gross acres (85,000 net acres) with five producing oil and gas wells, in which Petro owns a 50% working interest and 40% net revenue interest.
Petro River’s activities are focused on its oil properties in the Mississippi Lime play in eastern Kansas. The Company has accumulated close to 100,000 acres with an extensive inventory of low cost drilling opportunities with potential for high returns. At current commodity prices, Mississippi Lime wells are averaging a 80% rate of return. Petro River Oil also has significant acreage and oil reserves in Missouri.
Source: Petro River, OxBridge Research, Daily Stock Deal, OTCking
Don't miss the NEXT premium Alert! Sign-up, Get Alerts, MakeMoney!®
Disclaimer/Disclosure: we received or expecting compensation from the featured company. Our firm, principals and staff may own/buy/sell/trade stock/securities of this company. Always Read the full Disclosure/Disclaimer. Thanks.
OxBridge Research initiates coverage of Teryl Resources,TRC.V, with a price target of 14 cents
Teryl Resources, TRC.V / TRYLF
OxBridge Research, a leading provider of investment research and investor relations services, today announced that it has initiated coverage of Teryl Resources with a price target of 14 cents.
Teryl Resources is a Junior Gold Mining company with assets in Fairbanks Mining District in Alaska and British Columbia. The Fairbanks Mining District is one of Alaska’s largest gold producing areas – gold production of over 40 million ounces.
The 31 page Report covers, Teryl's properties, its various Joint Venture partners including Kinross Gold Corporation (KGC) and Linux Gold Corp. (LNXGF) and future Gold market outlook.
The full Report is available for download for FREE at http://www.oxbridgeresearch.com/ and http://www.terylresources.com/ in addition to this Initiation Report, OxBridge Research will also provide ongoing coverage and event-based research updates on the Company.
Company Description
Teryl Resources Corp., TRC.V, is an early stage Canadian junior precious metals acquisition, exploration, and development company which holds interests in gold and silver properties in Alaska and British Columbia, Canada. Click here for complete Executive Summary
The Company is an accomplished explorer with a proven track record of exploration, development, and marketing its properties to mining majors. The Company has three properties in Alaska and one property in British Columbia. Teryl’s properties in Alaska are in the Fairbanks Mining District and include the West Ridge Property, Fish Creek Property, and Stepovich Property. Learn more about Teryl's strategy, see the Investment Highlights
The Fairbanks Mining District is one of the largest gold producing areas in Alaska. In 2011, Teryl sold its 20% stake in Gil Properties to Kinross Gold for US$15 million. see Teryl's Valuation
The Company’s single property in British Columbia is its Silverknife Property. Teryl also has oil and gas properties in Texas and Kentucky. To date, Teryl has spent over $2.2 million on exploration of its properties. Find out why the Analyst thinks the stock is undervalued, read Investment Thesis now
Sources: Teryl Resources Corp., Kinross Gold Corp., Linux Gold Corp., SilverCorp.
Forward-looking statements:-The Company's actual results, performance or achievements could differ materially from those expressed in, or implied by, these forward-looking statements, including those described in the Company's Financial Statements, Management Discussion and Analysis and Material Change Reports filed with the Canadian Securities Administrators and available at www.sedar.com, and the Company's 20-F annual report filed with the United States Securities and Exchange Commission at www.sec.gov.
This profile/research report/email letter/blog/posting in forums/social-media/t/f does not constitute an offer to sell or a solicitation of an offer to buy any of the securities in the United States. The securities of the Company have not been registered under the United States Securities Act of 1933, as amended (the "U.S. Securities Act") or any state securities laws and may not be offered or sold within the United States or to U.S. Persons unless registered under the U.S. Securities Act and applicable state securities laws or an exemption from such registration is available. Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
Disclosure/Disclaimer:-OxBridge Research publishes sponsored research reports, advertorials and corporate profiles on its portal and several other websites/blogs, including this website/blog, owned and operated by OxBridge and/or its affiliates. OxBridge Research is not a Broker Dealer or a Registered Financial Adviser in any jurisdiction, whatsoever. All the information published on its website(s) and/or distributed to its members via various electronic means is for general awareness and entertainment purpose only. OxBridge urges investors to do their own due diligence and consult with their financial adviser prior to making any investment decision. We are expecting a payment of seven thousand dollars in compensation from the company/a third party/shareholder. We receive compensation from companies for providing various IR services, including consultation, publication, advertisement and social media awareness, therefore our views/opinion are inherently biased. Please read the full disclosure/disclaimer, if you need assistance contact This e-mail address is being protected from spambots. You need JavaScript enabled to view it OxbridgeResearch.com, All Rights Reserved. Trademarks/logos are of their respective owners. It's YOUR money -Invest WISELY TM
GenVec, GNVC, Profile, Summary
GenVec | GNVC | Profile | Summary
GenVec, (GNVC) is a biopharmaceutical company using differentiated, proprietary technologies to create superior therapeutics and vaccines. A key component of the company's strategy is to develop and commercialize products through collaborations. GenVec is working with leading companies and organizations such as Novartis, Merial, and the U.S. Government to support a portfolio of product programs that address the prevention and treatment of a number of significant human and animal health concerns.
GenVec’s development programs address therapeutic areas such as hearing loss, balance disorders, and cancer; as well as vaccines against infectious diseases including respiratory syncytial virus (RSV), herpes simplex virus type 2 (HSV-2), dengue fever, influenza, malaria, and human immunodeficiency virus (HIV).
The GenVec's Advantage
The company's core technology has the important advantage of localizing protein delivery in the body. This is accomplished by using adenovector platform to locally deliver genes to cells, which then direct production of the desired protein. This approach reduces side effects typically associated with systemic delivery of proteins. For vaccines, the goal is to induce an immune response against a target protein or antigen. This is accomplished by using an adenovector to deliver a gene that causes production of an antigen, which then stimulates the desired immune reaction by the body.
GenVec’s novel proprietary adenovectors
?
No pre existing immune recognition
?
Built on rare human and nonhuman adenovirus serotypes
?
New GC technology shows superior performance for genetic vaccines
?
Multiple capsid modified vectors -AdH technology
?
Multiple genes/multiple antigens
?
Targeted and specific delivery Proprietary adenovectors and cell lines
?
Novel proprietary non replicating adenovirus vectors
•
Very low sero -prevalence in humans
•
Outstanding gene/antigen delivery properties
?
Cell line master banks and master file with FDA
Hearing Restoration Molecular Therapeutic
•
Dengue Virus Genetic Vaccine
•
Foot and Mouth Virus Genetic Vaccine
•
Malaria Genetic Vaccine
•
RSV Genetic Vaccine
•
HSV Molecular Therapeutic and Genetic Vaccine
A platform of adenovirus vectors built to meet product needs for molecular therapeutics and genetic vaccines
Don't miss the NEXT premium Alert! Sign-up, Get Alerts, MakeMoney!®
we received or expecting compensation from the featured company. Our firm, principals and staff may own/buy/sell/trade stock/securities of this company. Always Read the full Disclosure/Disclaimer. Thanks. OTCKing.com is an OxBridge affiliate/partner website.
Disclosure/Disclaimer:- OxBridge Research publishes sponsored research reports, advertorials and corporate profiles on its portal and several other websites/blogs, including this website/blog, owned and operated by OxBridge and/or its affiliates. OxBridge Research is not a Broker Dealer or a Registered Financial Adviser in any jurisdiction, whatsoever. All the information published on its website(s) and/or distributed to its members via various electronic means is for general awareness and entertainment purpose only. OxBridge urges investors to do their own due diligence and consult with their financial adviser prior to making any investment decision. We are expecting a payment from the company/a third party/shareholder. We receive compensation from companies for providing various IR services, including publication, advertisement,and social media awareness, therefore our views/opinion are inherently biased. Please read the full disclosure/disclaimer, if you need assistance contact This e-mail address is being protected from spambots. You need JavaScript enabled to view it
OxbridgeResearch.com, All Rights Reserved. Trademarks/logos are of their respective owners.
It's YOUR money - Invest WISELY TM
- Teryl Resources, TRC.V/TRYLF, Profile
- Velti, VELT, Profile, Summary
- Anavex Life Sciences, AVXL, Profile, Summary
- FFFC, Fast Funds Financial, Profile, Life Collateralized Mortgage Obligagtion
- Titan Pharmaceuticals, TTNP, Profile
- GNIN, Green Innovations, Summary, Profile
- GETG, Green Earth Technologies, Summary, Profile
Feed Entries
